TrialEBioMedicine2026

Molecular pathways driving clarithromycin benefit in community-acquired pneumonia: analysis of the ACCESS randomised trial.

Emmanouil Stylianakis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.